**Setshaba Research Centre Publications**

1. Namey E, Agot K, **Ahmed K**, Odhiambo J, **Skhosana J**, Guest G and Corneli A. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. **Culture, Health & Sexuality 2016**. DOI: 10.1080/13691058.2016.1164899
2. Corneli A, Perry B, McKenna K, Agot K, **Ahmed K**, Taylor KJ, Malamatsho F, Odhiambo J, **Skhosana J** and Van Damme L. Participants’ Explanations for Nonadherence in the FEM-PrEP Clinical Trial. [**J Acquired Immune Deficiency Syndr**](http://www.ncbi.nlm.nih.gov/pubmed/25761233)**ome 2016.** 71 (4): 452-461.
3. [Corneli A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Corneli%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26895239), [Yacobson I](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yacobson%20I%5BAuthor%5D&cauthor=true&cauthor_uid=26895239), [Agot K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Agot%20K%5BAuthor%5D&cauthor=true&cauthor_uid=26895239) and [**Ahmed K**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ahmed%20K%5BAuthor%5D&cauthor=true&cauthor_uid=26895239)**.** Guidance for Providing Informed-Choice Counseling on Sexual Health for Women Interested in Pre-Exposure Prophylaxis in Kenya and South Africa. [**AIDS Patient Care STDS.**](http://www.ncbi.nlm.nih.gov/pubmed/26895239) **2016.** *Published ahead of print.*
4. [Deese J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Deese%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Masson L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Masson%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Miller W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Miller%20W%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Cohen M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cohen%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Morrison C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Morrison%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Wang M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [**Ahmed K**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ahmed%20K%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Agot K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Agot%20K%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Crucitti T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Crucitti%20T%5BAuthor%5D&cauthor=true&cauthor_uid=26202107), [Abdellati S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Abdellati%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26202107) and [Van Damme L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Van%20Damme%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26202107). Injectable Progestin-Only Contraception is Associated with Increased Levels of Pro-Inflammatory Cytokines in the Female Genital Tract. [**American Journal of Reproductive Immunolology.**](http://www.ncbi.nlm.nih.gov/pubmed/26202107) **2015;** 74 (4): 357-367.
5. **Malahleha M, Ahmed K**, Deese J, Nanda K, Van Damme L, De Baetselier I and Burnett RJ. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report. **Journal of Medical Case Reports 2015**; 9: 207. DOI 10.1186/s13256-015-0679-4.
6. Friedland BA, Stoner M, Chau MM, Plagianos MG, Govender S, Morar N, Altini L, Skoler-Karpoff S, **Ahmed K**, Ramjee G, **Monedi C,** Maguire R and Lahteenmaki P. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial. **Aids and Behaviour 2015**. DOI 10.1007/s10461-015-1123-x.
7. Corneli A, Namey E, **Ahmed K**, Agot K, **Skhosana J**, Odhiambo J and Guest G. Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. **Aids Patient Care and STDs 2015**; 29 (9): DOI: 10.1089/apc.2015.0038
8. Corneli A, Field S, Namey E, Agot K, **Ahmed K**, Odhiambo J, **Skhosana J** and Guest G. Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP. **PloS One 2015**; DOI:10.1371/journal.pone.0129177.
9. Kelly CA, Friedland BA, Morar NS, Katzen LL. , Ramjee G, Mokgatle MM and **Ahmed K**. Tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa. **Culture, Health & Sexuality 2015**. DOI: 10.1080/13691058.2015.1030451.
10. Agot K, Taylor D, Corneli A, Wang M, Ambia J, Kashuba A, Parker C, Lemons A, **Malahleha M**, Lombaard J, Van Damme L. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials**. AIDS Behav. 2015**; 19 (5): 743-751.
11. Corneli A, Perry B, Agot K, **Ahmed K**, Malamatsho F and Van Damme L. Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial. Plos One **2015**. DOI:10.1371/journal.pone.0125458.
12. Corneli A. L, McKenna K, Perry B, **Ahmed K,** Ago K, Malamatsho F, **Skhosana J,** Odhiambo J, Van Damme L. [The Science of Being a Study Participant: FEM-PrEP Participants' Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills](http://journals.lww.com/jaids/Fulltext/2015/04150/The_Science_of_Being_a_Study_Participant__.14.aspx). [**J Acquired Immune Deficiency Syndr**](http://www.ncbi.nlm.nih.gov/pubmed/25761233)**ome 2015**; 68 (5): 578-584.
13. Parker C, Corneli A, Agot K, Odhiambo J, Asewe J, **Ahmed K, Skhosana J,** Ratlhagana M, Lanham M, Wong C, Deese J, Manongi R, Van Damme L . Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial. **Open Access Journal of clinical Trials 2015**; 7: 1-9.
14. Callahan R, Nanda K, Kapiga S, **Malahleha M**, Mandala J, Ogada T, Van Damme L, Taylor D, for the FEM-PrEP Study Group. Pregnancy and Contraceptive Use Among Women Participating in the FEM-PrEPTrial. **Acquir Immune Defic. Syndr** **2015**; 68 (2): 196 – 203.
15. Mandala J, Nanda K , Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, **Malahleha M**, Manongi R, Taylor D and Van Damme L. Liver and renal safety of tenofovirdisoproxilfumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. **BMC Pharmacology and Toxicology** **2014**; 15 (1): 77.
16. Corneli A, Wang M, Agot K, **Ahmed K,** Lombaard J, Van Damme L, for the FEM-PrEP Study Group. [Perception of HIV Risk and Adherence to a Daily, Investigational Pill for HIV Prevention in FEM-PrEP](http://journals.lww.com/jaids/Fulltext/2014/12150/Perception_of_HIV_Risk_and_Adherence_to_a_Daily%2C.14.aspx). **Journal of Acquired Immune Deficiency Syndromes 2014**; 67 (5): 455-575.
17. Corneli AL, McKenna K, Headley J, **Ahmed K,** Odhiambo J, **Skhosana J**, Wang M and Agot K for the FEM-PrEP Study Group. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa**Journal of the International AIDS Society** **2014**, 17 (Suppl 2): 19152
18. Evens E, Tolley E, Headley J, McCarraher D, Hartmann M, Mtimkulu VT, **Manenzhe K**, Hamela G, Zulu F.  Identifying factors that influence pregnancy intentions: evidence from South Africa and Malawi. **Culture, Health and Sexuality 2014;** 29: 1-16.
19. Grant R.M, Liegler T, Defechreux P, Kashuba A.D.M, Taylor D, Abdel-Mohsen M., Deese J, Fransen K, De Baestelier I, Cricitti T, Bentley G, Agingu W, **Ahmed K** and Van Damme L. Drug resistance and plasma viral RNA level after ineffective use of pre-exposure prophlyaxi in Women. **AIDS 2014**; 29 (3): 331-337.
20. Headly J, Corneli A., Agot K, **Ahmed K**, Wang M, Odhiambo J, **Skhosana J**, Tharaldson J, van Damme L, MacQueen K, For the FEM-PrEP Study Group. The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa. **PloS One 2014;** 17: 9 (9).
21. Corneli AL, Deese J, Wang M, Taylor D, **Ahmed K**, Agot K, Lombaard J, Monangi R, Kapiga S, Kashuba A and van Damme L, for the FEM-PrEP Study Group. FEM-PEP Adherence Patterns and Factors Associated with Adherence to a Daily oral Study Product for Pre-exposure Prophylaxis. **Journal of Acquired Immune Deficiency Syndromes 2014;** 66 (3): 324-331.
22. Schenk KD, Friedland BA, Chau M, Stoner M, Plagianos MG, Skoler-Karpoff S, Palanee T, **Ahmed K**, Rathlagana MJM , Mthembu PN , and Ngcozela N. Enrollment of Adolescents Aged 16-17 Years Old in Microbicide Trials: An Evidence-Based Approach. **Journal of Adolescent Health 2014;** 54 (6): 654-662.
23. **Malahleha M**, Mokwena K, **Ahmed K**. Knowledge and Perceptions of Vaginal Microbicides among Healthcare Postgraduate Students at the University of Limpopo. **AIDS Res Hum Retroviruses 2014**; 30 (S1): A163-A164.
24. Mack N, Kirkendale S, Omullo P, Odhiambo J, Masiki M, Siguntu P, Ratlhagana M, Agot K, **Ahmed K**, Kapiga S, Lombaard J, van Damme L, Corneli A. Implementing good participatory practice guidelines in the FEM-PrEP Preexposure Profilaxis Trial for HIV Prevention Among African Women: a focus on local stakeholder involvement. **Journal of clinical Trials 2013**; 5:127-135.
25. **Ahmed K**, Malahleha M, Deese J, Monedi C and van Damme L. Elevated liver transaminases, human immune deficiency virus (HIV) seroconversion and rapid progression to AIDS in a HIV prevention clinical trial participant: A case report **Journal of AIDS and HIV Research 2013;** 5 (3): 65-69.
26. Van Damme L, Corneli A, **Ahmed K**, Agot K, Lombaard J, Kapiga S, **Malahleha M** al. Pre-exposure prophylaxis for HIV infection among African women. **The New England Journal of Medicine 2012**; 367: 411-422.
27. Morrison C, Skoler-Karpoff S, Kwoka C, Chena P L, Wijgert J, Gehret-Plagianos MPatel S, Ahmed K, et al. Hormonal Contraception and the Risk of HIV Acquisition among Women in South Africa. **AIDS 2012**; 4: 497-504.
28. Marais Gawarecki D, Allan B, **Ahmed K**, Altini L, **Cassim N**, Gopaleng F, Hoffman M, Ramjee G, Williamson A-L. The Effectiveness of Carraguard, a Vaginal Microbicide, in protecting women against high-risk Human Papilloma-Virus infection. **Antiviral therapy 2011;** 16 (8): 1219-1226.
29. Mensch BS, Hewett PC, Abbott S, Rankin J, Littlefield S, **Ahmed K**, **Cassim N**, Patel S, Ramjee G, Palanee T, Mierzwa S, Skoler-Karpoff S. Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa: An Interview Mode Experiment Using a Placebo Gel. **AIDS and Behaviour 2011;** 15: 407-421.
30. Said HM, **Ahmed K**, Burnett R, Allan BR, Williamson A-L, Hoosen, AA. HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community based Microbicide study in Pretoria, South Africa. **Journal of Clinical Virology 2009;** 44: 318-321.
31. Skoler-Karpoff S, Ramjee G, **Ahmed K**, Altini L, GehretPlagianos M, Friedland B, Govender S, De Kock A, **Cassim N**, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomized, double-blind, placebo-controlled trial**. Lancet 2008.** 372:1977-1987.
32. **Ahmed K, Cassim N**. HIV prevention using vaginal microbicides: an update. **JIMASA 2007;** 14: 11-14.
33. de Kock A, Skoler S, **Ahmed K**, Govender S. Enrolling Adolescents in Research on HIV: Young Women Must Be Included**. PLoS Med 2006;** 3 (12): 2458-2463.
34. SkolerS, Govender S, Altini L, **Ahmed K**, Waldron D, Myer L, Lahteenmaki P, Fleming Richardson B. Risks in the use of an unblinded-control group. **Journal of Infectious Diseases 2005;** 191: 1378-1380.
35. Skoler S, Govender S, Altini L, **Ahmed K**, Waldron D, Myer L, Lahteenmaki P. Control Groups in Microbicide Trials: In defense of Orthodoxy. Correspondence Article. **Journal of Infectious Diseases 2005;** 191: 1378-1379.